However, in our study, we found that PEDF inhibited hypoxia-induced NLRP3 inflammasome activation via PEDFR, not LR, in cardiomyocytes, which shows a new direction for the treatment of ischemic heart disease though inhibiting the innate immune response. This evidence concerns the gene NLRP3 and coronary artery disorder.